Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Radioiodination of Silodosin with ¹³¹I as a Selective Drug for Prostate Imaging in Mice.","authors":"Mahmoud H Sanad, Safaa B Challan, Fatma Y Abdou, M El-Desawy, Heba M Essam","doi":"10.1089/cbr.2025.0015","DOIUrl":"https://doi.org/10.1089/cbr.2025.0015","url":null,"abstract":"<p><p><b><i>Background:</i></b> Silodosin (Sild) is a selective α1A-adrenergic receptor antagonist effective in treating benign prostatic hyperplasia (BPH), a condition characterized by prostate enlargement, which leads to urinary dysfunction. <b><i>Objective:</i></b> This study aims to radiolabel Sildosin with iodine-131 [¹³¹I]) using chloramine-T(Ch-T), optimized the process to achieve high radiochemical yields, and investigated the [¹³¹I]Sildodosin [¹³¹I]Sild) radiotracer in the prostate of murine models. <b><i>Methods:</i></b> Compared to a control group, biodistribution studies were conducted to evaluate the [¹³¹I]Sild radiotracer uptake in mice with BPH. Biochemical analyses were performed to assess serum prostate-specific antigen (PSA) levels, antioxidant enzyme activities catalase (CAT) and superoxide dismutase (SOD), and oxidative stress markers such as malondialdehyde (MDA) in both groups. <b><i>Results:</i></b> The [¹³¹I]Sild radiotracer exhibited a radiochemical yield of 93.7 ± 1.1% and maintained stability for up to 4 h in serum. Biochemical markers indicated an increase in PSA, lipid peroxidation, MDA levels, and protein content, with an increase in prostate weight in mice with BPH compared to the control group. Histopathological examination revealed disruption of tissue growth and a localized inflammatory response in BPH compared to the control. Biodistribution studies demonstrated significant uptake of the [¹³¹I]Silodosin radiotracer in BPH, with a value of 7.6 ± 0.18% ID/g at 120 min post-administration. <b><i>Conclusion:</i></b> The results suggest that [¹³¹I]Silodosin radiotracer holds potential as an imaging agent for chronic prostatic diseases, particularly BPH.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Response to Letter:</i> \"Skin Cancer Detection Using Deep Learning Approaches\" by Haque et al.","authors":"Ilaria Proietti, Luca Filippi","doi":"10.1089/cbr.2025.0122","DOIUrl":"https://doi.org/10.1089/cbr.2025.0122","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EIF4A3-Induced hsa_circ_0118578 Expression Enhances the Tumorigenesis of Papillary Thyroid Cancer.","authors":"Chan Li, Ping Xie, Meng Luo, Kun Lv, Zewei Cong","doi":"10.1089/cbr.2024.0133","DOIUrl":"10.1089/cbr.2024.0133","url":null,"abstract":"<p><p><b><i>Background:</i></b> Circular RNA (circRNA) plays a regulatory role in the malignancy of papillary thyroid cancer (PTC). However, the role of a novel circRNA, hsa_circ_0118578, in PTC is not yet fully understood. This report focuses on unveiling hsa_circ_0118578's effect on PTC cell malignancy and reveals its mechanism in PTC progression. <b><i>Methods:</i></b> Levels of hsa_circ_0118578 in PTC were assessed by quantitative real-time polymerase chain reaction (qRT-PCR). The functional roles of hsa_circ_0118578 in PTC cell malignancy were evaluated through Transwell, 5-ethynyl-2<b>'</b>-deoxyuridine (EdU), and wound healing assays. A xenograft model in nude mice was used to examine the effects of hsa_circ_0118578's <i>in vivo</i>. The interaction between eukaryotic translation initiation factor 4A3 (EIF4A3) and hsa_circ_0118578 was confirmed using RNA-binding protein immunoprecipitation, qRT-PCR, and Western blotting. <b><i>Results:</i></b> Hsa_circ_0118578 with high expression in PTC tissues was associated with higher tumor node metastasis stage, lymph node metastasis, as well as poor differentiation. Cell functional assays demonstrated that silencing hsa_circ_0118578 inhibited PTC cell proliferation, invasion, and migration. In the xenograft assay, tumorigenicity of PTC cells <i>in vivo</i> was reduced following hsa_circ_0118578 suppression. Additionally, EIF4A3, as an RNA-binding protein, was shown to interact with hsa_circ_0118578 to stabilize its expression in PTC cells. <b><i>Conclusions:</i></b> Upregulated hsa_circ_0118578 in PTC interacts with EIF4A3 to exert oncogenic effects by enhancing hsa_circ_0118578 stability, contributing to PTC development. These findings shed light on the oncogenic role of hsa_circ_0118578 in PTC and suggest it as a potential therapeutic target.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"285-292"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneous Distribution and Absorbed Dose of Radiolabeled Nanoparticles and Colloids in Sentinel Lymph Nodes.","authors":"Renata Madru, Erik Larsson, Anders Örbom, Christian Ingvar, Dorthe Grabau, Linda Knutsson, Sven-Erik Strand","doi":"10.1089/cbr.2024.0111","DOIUrl":"10.1089/cbr.2024.0111","url":null,"abstract":"<p><p><b><i>Background:</i></b> For breast cancer staging, radiolabeled colloids and superparamagnetic iron oxide nanoparticles (SPIONs) are used for sentinel lymph node (SLN) imaging. This study characterized the intranodal activity distribution and absorbed dose distribution. <b><i>Material and Methods:</i></b> Six patients diagnosed with primary breast cancer were intradermally injected with ^99mTc-Nanocoll. The SLNs were resected, weighed, and measured for activity. Three groups of six rats were subcutaneously injected into the hind paw with either ^99mTc-Nanocoll, ^99mTc-SPIONs, or ⁶⁸Ga-SPIONs. Macro- and small-scale dosimetry calculations were performed using autoradiography images of cryosections of SLNs from patients and animals. <b><i>Results:</i></b> The mean absorbed dose in patient SLNs was 0.5 ± 0.3 mGy/MBq for ^99mTc-Nanocoll and 3.4 ± 1.8 mGy/MBq, assuming a ^99mTc-Nanocoll-based distribution of ⁶⁸Ga-SPIONs. Due to different decay characteristics, the heterogeneity in the absorbed dose differed between ^99mTc-SPIONs and ⁶⁸Ga-SPIONs with a maximum to mean absorbed dose ratio of 2.7 ± 0.3 and 1.6 ± 0.2, respectively. <b><i>Conclusions:</i></b> This study shows that ^99mTc- and ⁶⁸Ga-SPIONs and ^99mTc-nanocolloids have similar activity distribution in human and animal lymph nodes. Small-scale dosimetry models combined with clinical patient biokinetics may serve as a bridge between organ and tissue dosimetry and the interpretation of intrinsic geometric variation and its uncertainties in absorbed dose.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"254-262"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anlotinib as a Tailored Treatment for Extensive-Stage Small Cell Lung Cancer with Stable Disease after Two Cycles of First Chemotherapy Plus Immunotherapy: A Retrospective Study.","authors":"Yonghong Li, Xi Lin, Yi Peng, Jing Tang, Xiaobing Li","doi":"10.1089/cbr.2024.0220","DOIUrl":"https://doi.org/10.1089/cbr.2024.0220","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Optimize the treatment of extensive-stage small cell lung cancer (ES-SCLC). <b><i>Materials and Methods:</i></b> We collected data on patients with ES-SCLC who had stable disease (SD) after two cycles of first-line chemotherapy combined with immunotherapy (CIO) and subsequently received tailored treatment with anlotinib. The primary endpoints of the study were progression-free survival and overall survival (OS), while secondary endpoints included overall response rate (ORR), disease control rate (DCR), and adverse events (AEs). <b><i>Results:</i></b> A total of 45 patients were ultimately enrolled in the study. Preliminary analysis indicated that the integration of anlotinib provides promising efficacy for patients with ES-SCLC who had SD after two cycles of CIO. ORR and DCR were 26.67% and 62.22%, respectively, with median progression-free survival and median OS were 6.0 months and 10.0 months. Furthermore, subgroup analysis results showed that patients who experienced hypertension, proteinuria, and hand-foot syndrome during treatment had better efficacy. In addition, mechanistic analysis suggested that this regimen may activate the immune system by depleting immune suppression, thereby exerting a synergistic antitumor effect. Beyond the promising efficacy, the overall AEs of this regimen were manageable, indicating a potential positive outlook for this treatment model in this patient population. <b><i>Conclusion:</i></b> The adaptive treatment with anlotinib can significantly improve outcomes for these patients, with manageable toxicities, suggesting that this treatment model has the potential to become an important option for first-line therapy in ES-SCLC. However, its true clinical value requires further research for validation.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":"40 4","pages":"277-284"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress of Hyaluronic Acid-Coated Nanocarriers in Targeted Cancer Therapy.","authors":"Xinxin Hou, Hao Zhang","doi":"10.1089/cbr.2024.0143","DOIUrl":"10.1089/cbr.2024.0143","url":null,"abstract":"<p><p><b><i>Background:</i></b> Hyaluronic acid (HA), as a critical ingredient of extracellular matrix (ECM) and synovial fluid, has attracted extensive attention in targeted tumor thearpy. The superiority of HA is reflected as its great biocompatibility, biodegradability and special binding ability to CD44 receptor. Moreover, CD44 receptor proteins are overexpressed in many kinds of tumor cells and cancer stem cells (CSCs). Therefore, HA is commonly used as ligands for the surface modification of versatile nanocarriers applied in various tumor therapy approaches. <b><i>Methods:</i></b> We reviewed the literature and summarized the unique properties of HA, the rationale for the use of HA as tumor-specific carrier for drug delivery, catabolism of HA coated nanocarriers, and research achievements of frequently-used HA-modified organic and inorganic nanocarries. <b><i>Results:</i></b> We concluded the significant applications of HA coated nanocarriers in tumor chemotherapy and chemoresistance, combination therapy and cancer theranostics. <b><i>Conclusion:</i></b> The application prospect of HA-coated nanocarriers will be more extensive for various targeting combination therapy and theranostics.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"231-243"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Role of [⁶⁸Ga]Ga-DOTAGA-IAC and Comparison of Its Diagnostic Performance with [¹⁸F]F-FDG PET/CT in Radioiodine Refractory Differentiated Thyroid Carcinoma.","authors":"Srinivas Ananth Kumar, Ashwani Sood, Rajender Kumar, Somit Pandey, Jaya Shukla, Bhagwant Rai Mittal, Stanley Satz","doi":"10.1089/cbr.2024.0166","DOIUrl":"10.1089/cbr.2024.0166","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Integrin antagonist complex (IAC), a novel α_vβ₃ integrin antagonist peptidomimetic, has emerged as a promising agent for molecular imaging of tumor angiogenesis. This study evaluates the biodistribution and clinical efficacy of [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT in detecting radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), comparing its diagnostic performance with [¹⁸F]F-FDG PET/CT. <b><i>Materials and Methods:</i></b> In this prospective pilot study, RAIR-DTC patients underwent whole-body imaging with [¹⁸F] F-FDG PET/CT, followed by [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT. Biodistribution patterns of [⁶⁸Ga]Ga-DOTAGA-IAC were assessed. Lesions with abnormal, nonphysiologic tracer uptake (showing activity exceeding mediastinal blood pool) were considered positive for disease. Imaging findings were compared between the two modalities, and quantitative metrics, including SUV_max, metabolic tumor volume, and total lesion glycolysis, were analyzed statistically. <b><i>Results:</i></b> Among 30 patients with RAIR-DTC, [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT revealed predominant physiological tracer uptake in the kidneys. [¹⁸F]F-FDG PET/CT identified 97 lesions, predominantly nodal (73.2%), while [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT detected 34 lesions, 50% of which were nodal. Few patients exhibited multiple lesions with varying uptake grades, with 20% showing coexisting higher-grade lesions (grade II or above) on [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT. <b><i>Conclusion:</i></b> Angiogenesis imaging using [⁶⁸Ga]Ga-DOTAGA-IAC PET/CT demonstrates limited sensitivity for lesion detection in patients with RAIR-DTC compared with [¹⁸F]F-FDG PET/CT. However, the potential of [⁶⁸Ga]Ga-DOTAGA-IAC as a diagnostic tool for other cancers has been used in other cancers with positive imaging characteristics warranting further exploration.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"270-276"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetry Assessment in Predicting Treatment Outcomes Following Yttrium-90 Transarterial Radioembolization of Hepatic Tumors.","authors":"Christina Ward, Sandon Scott, William Wesson, Jared Mazurek, Ian Kozlowski, Gregg Werner, Arshan Dehbozorgi, Milind Phadnis, Carissa Walter, Aaron Rohr, Zachary Collins","doi":"10.1089/cbr.2024.0194","DOIUrl":"10.1089/cbr.2024.0194","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To evaluate the use of yttrium-90 (⁹⁰Y) dosimetry in predicting treatment outcomes when used following transarterial radioembolization with SIR-Spheres® (Resin ⁹⁰Y) in patients with hepatic tumors. <b><i>Materials and Methods:</i></b> This single institution retrospective analysis included 100 patients with hepatocellular carcinoma, colorectal carcinoma or other liver metastases who underwent transarterial radioembolization with resin ⁹⁰Y and had imaging follow-up within one year of treatment. Mean tumor dose and mean dose to nontumor was calculated using voxel-based dosimetry software. Descriptive statistics were reported and methods of analyses included simple and multivariable linear regression, contingency table analyses, Kaplan-Meier estimation, and Cox proportional hazards models. <b><i>Results:</i></b> Of 100 patients included, 65 demonstrated tumor shrinkage following transarterial radioembolization. Of these, 20 (30.8%) had hepatocellular carcinoma, 22 (33.8%) had colorectal carcinoma, and 23 (35.4%) had other types of metastases. There was an association between tumor shrinkage and mean tumor dose (<i>p</i> = 0.0285) and mean dose to nontumor (<i>p</i> = 0.0028) in hepatocellular carcinoma patients, but not colorectal carcinoma, or the other subgroup. For all 100 patients, time to death and mean tumor dose was associated only in the other subgroup (<i>p</i> = 0.0260), but not in the hepatocellular or colorectal carcinoma groups. Time to death and mean dose to nontumor was associated in hepatocellular carcinoma patients (<i>p</i> = 0.0421), but not the colorectal carcinoma or other subgroup. <b><i>Conclusions:</i></b> Voxel-based dosimetry assessment is a tool that may be utilized to assist in predicting treatment outcomes in responders to transarterial radioembolization.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"244-253"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbial Cytotoxic Effect of ²¹²Pb in Radiopharmaceuticals.","authors":"Aaron T Schatzmann, Tania A Stallons, Rachel Rivera, Quy P Nguyen, Rémy Dureau, Julien J Torgue","doi":"10.1089/cbr.2024.0208","DOIUrl":"10.1089/cbr.2024.0208","url":null,"abstract":"<p><p><b><i>Background:</i></b> The cytotoxic effect of ²¹²Pb on microbial growth was examined, using six microorganisms, at clinically relevant time points, to determine the potency of ²¹²Pb as a self-sterilizing agent in radiopharmaceuticals using [²¹²Pb]Pb-DOTAMTATE. <b><i>Materials and Methods:</i></b> Vials of radiolabeled [²¹²Pb]Pb-DOTAMTATE, nonradiolabeled DOTAMTATE, and appropriate media were inoculated with <i>Bacillus spizizenii</i>, <i>Candida albicans, Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus,</i> or <i>Aspergillus brasiliensis</i>. Samples from each vial type were plated onto tryptic soy agar or Sabouraud dextrose plates and allowed to grow at optimal temperature for each strain to obtain quantifiable colony forming units (CFU). <b><i>Results:</i></b> Each microbial organism observed at least a 6 log reduction in total CFUs after 6 h of exposure to [²¹²Pb]Pb-DOTAMTATE drug product vials, showing no remaining colonies as compared to the vials containing only media and drug formulation with no radiolabeled material, utilizing a low absorbed dose of no greater than 1.01 kGy. A sterility assessment of the two [²¹²Pb]Pb-DOTAMTATE drug product vials containing the lowest total CFUs per vial displayed no microbial growth upon incubation for 14 d. <b><i>Conclusions:</i></b> This study suggests that ²¹²Pb in radiopharmaceuticals is a potent microbial cytotoxic agent with self-sterilizing properties.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"263-269"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143528064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation into the Spatial Heterogeneity of Lung Composite Large-Cell Neuroendocrine Carcinoma Spatial Transcriptomic Analysis of Combined Large-Cell Neuroendocrine Carcinoma.","authors":"Mingyu Ji, Daming Fan, Yaqi Yuan, Jing Wang, Xiaodong Feng, Weihua Yang, Xiaofei Dang, Yihui Xu, Jun Wang","doi":"10.1089/cbr.2025.0043","DOIUrl":"https://doi.org/10.1089/cbr.2025.0043","url":null,"abstract":"<p><p><b><i>Background:</i></b> Lung combined large-cell neuroendocrine carcinoma (CoLCNEC) refers to lung regions exhibiting both the features of large-cell neuroendocrine carcinoma (LCNEC) and the defined components of nonsmall cell lung cancer (NSCLC), with a relatively high mitotic rate. Diagnosing and predicting the prognosis of CoLCNEC are challenging. This study aimed to explore spatial transcriptomic expression patterns and identify crucial genes. <b><i>Methods:</i></b> We utilized a sample from a CoLCNEC patient containing three distinct components, namely, LCNEC, adenocarcinoma, and squamous cell carcinoma, with the former being predominant. Spatial transcriptomics (ST) technology, which employs the 10× Genomics Visium formalin-fixed paraffin-embedded ST kit, was applied along with high-throughput sequencing to obtain gene expression information and spatial locations for each spot. Subsequent analysis included differentially gene expression and functional enrichment. Finally, immunohistochemistry was employed to validate the marker protein structural maintenance of chromosomes 1A (<i>SMC1A</i>). Then, <i>SMC1A</i> was overexpressed and silenced in NCI-H661 and LTEP-a-2 cells, and the migration and invasion ability of the cells were detected by scratch assay and Transwell, respectively. The role of <i>SMC1A</i> in cancer cell cycle was detected by Real-time Reverse Transcription-PCR(RT-qPCR), Western blot, and flow cytometry, the apoptosis was detected by flow cytometry. <b><i>Results:</i></b> The results revealed that tumor tissue regions had higher unique molecular identifiers and gene counts than nontumor regions did. Unsupervised clustering identified four clusters, revealing the uniform distribution of unique transcripts, which were mapped onto slices to display apparent spatial separation. Differentially gene expression analysis revealed genes highly expressed in cancer cells. Further analysis of different regions revealed distinct cellular subgroups enriched through differentially gene expression analysis in various pathways, such as the cell cycle and DNA replication. Finally, <i>SMC1A</i> was chosen as a candidate gene, and immunohistochemistry confirmed its elevated expression in tumor regions. In addition, compared with oe-NC, oe-<i>SMC1A</i> can significantly promote the migration, invasion and G1/S phase transition of lung cancer cells, and promote the inhibition of apoptosis of cancer cells, while sh-<i>SMC1A</i> is completely opposite. <b><i>Conclusions:</i></b> In the tumor region of CoLCNEC, <i>SMC1A</i> is significantly upregulated. Moreover, silencing <i>SMC1A</i> effectively inhibits lung cancer cell invasion, migration, and G1/S phase transition, while promoting apoptosis. These findings indicate that <i>SMC1A</i> has the potential to be a new therapeutic target for CoLCNEC treatment.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}